Literature DB >> 12505687

Recent advances in the synthesis of endocannabinoid related ligands.

R K Razdan1, A Mahadevan.   

Abstract

The chemical strategies used for the synthesis of various ligands related to the endocannabinoid system namely anandamide (AEA), 2-arachidonylglycerol (2-Ara-Gl), CB1/(vanilloid receptors) VR1, anandamide membrane transporter (AMT) and fatty acid amide hydrolase (FAAH) are described in this review. In general, the chemical synthesis of analogs with changes in the head group of AEA was quite straightforward involving the conversion of an acid to an amide or an ester. Analogs which had modifications in the end pentyl chain were more difficult to synthesize and required multistep synthetic sequences to prepare the target compounds. A facile total synthesis of 2-Ara-Gl was reported and an HPLC procedure for its identification and quantification was developed, but because of the instability of 2-Ara-Gl another synthesis was developed so that it can be stored as the more stable phenylboronate ester. Similarly the chemical synthesis of various ligands in the remaining areas of CB1/VR1, AMT and FAAH are described. A summary of the present state of knowledge about the SAR in each area is presented to help in the design and synthesis of novel ligands for the future.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12505687     DOI: 10.1016/s0009-3084(02)00142-1

Source DB:  PubMed          Journal:  Chem Phys Lipids        ISSN: 0009-3084            Impact factor:   3.329


  2 in total

1.  Asymmetric synthesis of novel N-(1-phenyl-2,3-dihydroxypropyl)arachidonylamides and evaluation of their anti-inflammatory activity.

Authors:  Padmanabha V Kattamuri; Rebecca Salmonsen; Catherine McQuain; Sumner Burstein; Hao Sun; Guigen Li
Journal:  Life Sci       Date:  2012-07-20       Impact factor: 5.037

Review 2.  Further advances in the synthesis of endocannabinoid-related ligands.

Authors:  Anu Mahadevan; Raj K Razdan
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.